Taiwan’s Lotus Pharma inks biosimilars agreement with Alvotech for US and selected Asian markets
Taiwan-based Lotus P
Read More
製藥
Over 700 Pharma & Biotech players across Asia and beyond to gather in Singapore
Returning on 18- 20 March 2019 after a successful 2018 debut, Phar-East will once again bring together experts from Asian pharma & biotechs, big pharma, regulators, payers, technology innovators and more to share their expertise and chart Asia’s path forward.
Read More
Clinical trial partnerships with Australia: A US pharmaceutical firm case study
In the lead up to the Bio Connections Australia 13-14 November, Melbourne conference, we spoke with US-based pharmaceutical firm, Cerebral Therapeutics, who have recently undertaken a proof of concept clinical study in Australia, using a proprietary formulation to treat refractory epilepsy.
Read More
China’s leading Biopharma event concludes successfully with 400+ industry attendees
Organised by IBC Asia, the annual Biopharma Development & Production (BDP) Week took place on 16 – 17 May 2018 at Hilton Shanghai Hongqiao Hotel.
Read More
Lumosa Therapeutics partners with Camargo Pharmaceutical Services for the development of its analgesic in the US
Taipei, Taiwan-based Lumosa Therapeutics Co., Ltd., a company focused on developing treatments for neurological and inflammatory disease, announced recently that it had engaged Cincinnati-headquartered Camargo Pharmaceutical Services for regulatory consulting and strategic development services for LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US.
Read More
2017台灣生技月閉幕, 逾350場媒合會, 生技月讓世界看見台灣
亞洲生技產業年度盛會–2017台灣生技月(BioTaiwan 2017)活動於6月28日-7月2日於南港舉辦，並於今日(7/2)閉幕。總計今年共有超過600家國內外指標性大廠與1310個攤位參與生技展，吸引超過9萬人次進場參觀，促成近350場的商機媒合。
Read More